LLY Maintained at Overweight by Morgan Stanley, May 2026

Morgan Stanley maintained its Overweight rating on Eli Lilly (LLY) on May 1, 2026, signaling continued confidence in the pharmaceutical giant. The analyst firm raised its price target to $1,344 from $1,327, reflecting modest upside potential. This analyst rating maintained stance comes as LLY trades near $963, up 3.1% on the day. The company’s $910.5 billion market cap positions it as a healthcare heavyweight. Meyka AI rates LLY with a grade of B+, reflecting solid fundamentals across growth metrics and sector performance.

Morgan Stanley Maintains Overweight Rating

Morgan Stanley’s analyst rating maintained decision underscores steady confidence in Eli Lilly’s business trajectory. The firm raised its price target by $17 to $1,344, suggesting approximately 39% upside from current levels. This analyst rating maintained action reflects the analyst’s belief in LLY’s competitive positioning within drug manufacturing. The stock currently trades at $963.33 with a PE ratio of 34.26, indicating premium valuation typical for high-growth pharma. Morgan Stanley raised the price target to $1,344 from $1,327, signaling incremental optimism about near-term catalysts.

Strong Consensus Among Analysts

The broader analyst community shows overwhelming support for LLY. Forty analysts rate the stock as Buy, while only four maintain Hold positions. This consensus score of 3.0 reflects strong bullish sentiment across the Street. No analysts rate LLY as Sell or Strong Sell, demonstrating unified confidence. The analyst rating maintained by Morgan Stanley aligns with this broader market view. This near-unanimous backing suggests limited downside risk from analyst downgrades.

Price Target Implications

The $1,344 price target implies meaningful upside from current trading levels. At $963.33, investors would gain approximately 39% if the target is achieved. This analyst rating maintained with higher targets reflects confidence in LLY’s pipeline and market position. The company’s strong earnings growth of 95.6% year-over-year supports such optimism. Free cash flow surged 20.7% annually, providing resources for R&D and shareholder returns.

Eli Lilly’s Financial Strength and Growth

Eli Lilly demonstrates robust financial performance across multiple metrics. Revenue grew 44.7% year-over-year, while operating income jumped 69.7%. The company generated $22.9 billion in operating cash flow per share and $15.2 billion in free cash flow per share. Net profit margin stands at 35%, well above industry averages. LLY’s market cap of $910.5 billion reflects its status as a healthcare leader.

Profitability and Margins

Gross profit margin of 83.5% showcases LLY’s pricing power and operational efficiency. Operating profit margin of 45.9% demonstrates strong cost control. The company maintains a healthy current ratio of 1.50, indicating solid liquidity. Return on equity of 101.3% reflects exceptional capital efficiency. These metrics support the analyst rating maintained at Overweight.

Cash Generation and Dividends

Operating cash flow grew 90.7% year-over-year, providing ample resources for growth investments. Free cash flow surged 20.7%, reaching $15.2 billion per share. The dividend yield of 0.65% with $6.23 per share payout reflects shareholder-friendly capital allocation. Interest coverage of 37.5x demonstrates minimal financial risk. Debt-to-equity ratio of 1.39 remains manageable for a company of LLY’s scale.

Meyka AI Grade and Technical Outlook

Meyka AI rates LLY with a grade of B+, reflecting balanced fundamentals and growth prospects. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The scoring algorithm assigns 16% weight to sector comparison and 16% to industry metrics. Financial growth accounts for 12% of the grade, while forecasts contribute 8%. Analyst consensus carries 14% weight, and fundamental growth represents 7%. These grades are not guaranteed and we are not financial advisors.

Technical Indicators and Momentum

The RSI of 57.95 suggests neutral momentum without overbought conditions. MACD shows a negative histogram of 5.02, indicating weakening momentum. The ADX of 19.87 signals no clear trend direction. Bollinger Bands place the stock near the middle band at $916.60, suggesting equilibrium. Stochastic %K of 57.70 indicates moderate upside potential without extreme overbought signals.

Price Forecasts and Valuation

Meyka’s AI forecasts project LLY reaching $1,152.87 within one year. Three-year forecasts suggest $1,504.35, while five-year projections reach $1,855.21. These targets align with Morgan Stanley’s $1,344 price target. The PEG ratio of 0.27 indicates attractive valuation relative to growth rates. Price-to-sales ratio of 12.59 reflects premium positioning justified by growth metrics.

Healthcare Sector Dynamics and Competitive Position

Eli Lilly operates in the Drug Manufacturers – General segment within Healthcare. The company’s diversified portfolio spans diabetes, oncology, immunology, and neuroscience. Key products include Trulicity for diabetes, Verzenio for breast cancer, and Taltz for autoimmune conditions. The analyst rating maintained reflects confidence in this product mix. LLY’s 47,000 employees support operations across multiple therapeutic areas.

Research and Development Investment

R&D spending represents 19.5% of revenue, demonstrating commitment to innovation. The company invests heavily in pipeline development for future growth. This investment level supports the Overweight rating from Morgan Stanley. Strong earnings growth of 95.6% validates the effectiveness of R&D spending. The company’s focus on high-value therapeutic areas positions it well for future success.

Market Position and Competitive Advantages

With a $910.5 billion market cap, LLY ranks among the world’s largest pharmaceutical companies. The analyst rating maintained by Morgan Stanley reflects recognition of competitive moats. Strong brand recognition and patent portfolios provide pricing power. The company’s ability to generate 83.5% gross margins demonstrates market strength. Collaborations with firms like Incyte and Boehringer Ingelheim expand pipeline reach.

Final Thoughts

Morgan Stanley’s Overweight rating and $1,344 price target reflect strong confidence in Eli Lilly’s growth prospects. The company’s exceptional fundamentals, including 44.7% revenue growth and 95.6% earnings growth, support the bullish outlook. With 40 of 44 analysts rating the stock as Buy and Meyka AI assigning a B+ grade, consensus remains positive. While the 34.26x PE valuation is premium, it appears justified by LLY’s robust cash generation and long-term growth potential, making it an attractive healthcare investment.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Analyst ratings are opinions and not guarantees of future performance. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.